Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp reduced its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 467,962 shares of the life sciences company's stock after selling 15,830 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.61% of Integra LifeSciences worth $10,613,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in IART. Access Investment Management LLC acquired a new stake in shares of Integra LifeSciences in the fourth quarter worth approximately $4,416,000. Leeward Investments LLC MA grew its stake in shares of Integra LifeSciences by 7.8% during the 4th quarter. Leeward Investments LLC MA now owns 405,506 shares of the life sciences company's stock valued at $9,197,000 after buying an additional 29,402 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Integra LifeSciences by 5.5% during the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock worth $9,603,000 after buying an additional 22,000 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Integra LifeSciences in the 4th quarter worth $180,000. Finally, Choreo LLC boosted its holdings in Integra LifeSciences by 29.9% in the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock valued at $500,000 after acquiring an additional 5,123 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Separately, Morgan Stanley assumed coverage on Integra LifeSciences in a research note on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Stock Up 3.4 %

Shares of IART stock traded up $0.77 during mid-day trading on Monday, reaching $23.12. 389,562 shares of the company were exchanged, compared to its average volume of 1,004,698. The company has a market capitalization of $1.79 billion, a P/E ratio of -256.86, a P/E/G ratio of 0.73 and a beta of 1.23. The business's 50 day simple moving average is $23.78 and its 200 day simple moving average is $21.97. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $35.49.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.89 EPS. Research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.